Currently, ligands of the prostate-specific membrane antigen (PSMA) are the most promising PET tracer for PCa imaging [17] and both 68Ga- and 18F-labeled PSMA ligands are under clinical evaluation. The gene discussed is FOLH1; the disease is posterior cortical atrophy.